

FOI REF: 22/015

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

19th January 2022

Tel: 0300 131 4500

Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Could you provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

• Abatacept [Orencia]	30
• Adalimumab [Humira]	27
• Adalimumab Biosimilars	254
• Apremilast [Otezla]	9
• Baricitinib [Olumiant]	82
• Certolizumab [Cimzia]	26
• Etanercept [Enbrel]	19
• Etanercept Biosimilars	234
• Filgotinib [Jyseleca]	0
• Golimumab [Simponi]	59
• Guselkumab [Tremfya]	0
• Infliximab [Remicade]	<5
• Infliximab Biosimilars	72
• Ixekizumab [Taltz]	<5
• Risankizumab [Skyrizi]	0
• Rituximab [MabThera]	<5
• Rituximab Biosimilars	73
• Sarilumab [Kevzara]	8
• Secukinumab [Cosentyx]	86
• Tocilizumab [Ro Actemra]	71
• Tofacitinib [Xeljanz]	15
• Upadacitinib [Rinvoq]	0
• Ustekinumab [Stelara]	6

Please see above for the number of drug issues from our Pharmacy Department, for the Period October to December 2021, where the specialty on the patient episode at the time was rheumatology.

Cont.../

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net